Brief: Gilead Exercises Option To License Nurix’S Irak4 Targeted Protein Degrader Development Candidate, Nx-0479
20/03/2023 12:38
March 20 (Reuters) - Gilead Sciences Inc GILD.O :
* GILEAD EXERCISES OPTION TO LICENSE NURIX’S IRAK4 TARGETED
PROTEIN DEGRADER DEVELOPMENT CANDIDATE, NX-0479
* GILEAD SCIENCES INC - NURIX TO RECEIVE A $20 MILLION
OPTION FEE
Source text for Eikon: ID:nGNX870s4y
Further company coverage: GILD.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis